Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.

This study systematically evaluates the efficacy of a highly promising neuromodulation strategy - continuous theta burst (cTBS) transcranial magnetic stimulation - as a tool to change alcohol use behavior (Aim 1) and neurobehavioral concomitants of that behavior (Aim 2) in non-treatment seeking individuals with alcohol use disorder (AUD). In addition, we can begin to test prediction of individual treatment response based on an electrocortical signature of sign tracking (exploratory aim). This study is a double-blind, active sham-controlled study in community dwelling, non-treatment seeking individuals who meet DSM 5 criteria for AUD. Participants will be randomized to one of three groups: cTBS to ventromedial prefrontal cortex, cTBS to pre-supplementary motor area, or sham stimulation (10 sessions in one day). Participants will undergo comprehensive outcomes assessment, with measures including pre- and immediately post-cTBS clinical assessments (e.g., interview, Timeline Follow-back), alcohol craving tests, structural and fMRI, MRS, and EEG/ERP during salience- and cognitive flexibility-related tasks. To test alcohol craving and also use in alcohol-available settings, participants will complete a bar-lab session post-cTBS only (to avoid potential habituation to alcohol cues within the laboratory setting). Finally at 1-week post-treatment participants will complete craving and Timeline Follow-back measures remotely via REDCap.

The purpose of this study is to evaluate the efficacy and safety of ibuzatrelvir with and without remdesivir compared with remdesivir alone for the treatment of symptomatic COVID-19 in adult participants who are severely immunocompromised. This study is being done to learn how the study drug, called ibuzatrelvir, works in treating people with COVID-19 who have a severely compromised immune system. Ibuzatrelvir stops the virus that causes COVID-19 from multiplying in cells and spreading around the body. It may help people to get better and stay out of the hospital.

This study is recruiting pediatric patients who have been diagnosed with osteosarcoma. Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. The goal of the study is to determine the feasibility of adding cabozantinib to standard MAP (high dose methotrexate, doxorubicin, and cisplatin) chemotherapy in patients with newly diagnosed metastatic osteosarcoma with a resectable primary tumor and to compare the effects, good and/or bad, of cabozantinib in combination with MAP versus MAP alone on people with newly diagnosed OST to find out which is better. Common side effects of chemotherapy include nausea, vomiting, hair loss, and fatigue (tiredness). Participants will receive the medications through an IV in their arm and PO. Study participation is expected to last up to 16 months.

Feeding requires babies to coordinate sucking and swallowing, which depends on healthy brain development. Some newborns who experience brain injury or serious illness cannot safely practice feeding by mouth, which disrupts the development of these important brain circuits. As a result, many of these infants require a feeding tube placed in the stomach (called a G-tube) when they leave the hospital. Unfortunately, long-term feeding tube dependence is linked to poorer growth, delayed development, and breathing problems. Despite how common and serious these feeding difficulties are, there are currently no effective therapies for infants with the most severe swallowing problems. This study will test a non-invasive therapy called transcutaneous auricular vagus nerve stimulation (taVNS), which gently stimulates a nerve in the ear that connects to the brain. When paired with structured oral motor exercises, this approach may help strengthen the brain circuits needed for feeding. We will study 12 infants with severe feeding impairments to evaluate whether this therapy is safe, feasible, and shows early signs of benefit. This project will provide early evidence about whether a targeted brain-based therapy can improve feeding outcomes during a key window of early development.

This study is being done to determine whether the rates of birth defects, miscarriages, premature births and other outcomes in women with inflammatory bowel disease (IBD) taking azathioprine/6MP or biologic therapy or small molecules are different from those among IBD-affected women not taking these medications. Participants will be asked to give blood samples to assess drug levels during pregnancy and after birth. They will also be asked to answer questionnaires about their and their baby's health.

The purpose of this pilot study is to refine a mobile app, based on usability data, from 15 adults living with pulmonary hypertension (PH). The app is intended to reduce symptom burden and improve health-related quality of life for adults with PH, a chronic and debilitating cardiopulmonary condition. Participants will be asked to use the app and provide their thoughts about how to make it better by completing surveys and through interview. We also aim to assess readiness for broader implementation through surveys and targeted interviews with PH providers (N=15). Optimizing barriers and facilitators to implementation and gathering clinician perspectives will inform the design of a future randomized controlled feasibility trial.

A single weight based dose of alcohol will be given to approximate an alcohol binge (aiming to achieve a blood alcohol concentration of approximately 0.08%) to investigate downstream effects on intestinal permeability and changes in hepatic steatosis. Several studies have been performed in humans under similar conditions and looking at similar things. The PI, Dr. Garth Swanson, conducted one of these studies previously. Here, participants will be given a weight-based dose (2mL vodka per kg body weight) of alcohol, with assessment of intestinal permeability via urine collection over the 24 hours directly following alcohol consumption, assessment of changes in hepatic steatosis by evaluation with fibroscan before and after alcohol consumption, and blood markers of endotoxemia and related inflammatory markers after. The weight-based dosing of alcohol was chosen to reflect previous studies looking at the effects of a single episode of alcohol binge use, with the goal of achieving a blood alcohol concentration of approximately 0.08%, the lower limit of what is needed to be considered an acute alcohol binge.

The purpose of this study is to evaluate whether neuromuscular electrical stimulation (NMES) can help preserve muscle strength and muscle thickness in individuals living with amyotrophic lateral sclerosis (ALS). ALS is a progressive disease that causes weakness and muscle loss over time. NMES is a therapy that uses small electrical impulses delivered through adhesive pads placed on the skin to stimulate muscles to contract.
Participants in this study will use a portable NMES device at home approximately three times per week for 12 weeks. One muscle group will receive active electrical stimulation while the same muscle group on the opposite side of the body will receive low-intensity stimulation that does not produce a visible muscle contraction. This allows researchers to compare the effects of stimulation within the same participant.
During the study, participants will attend periodic clinic visits where researchers will measure muscle strength, evaluate muscle thickness using ultrasound, and ask questions about symptoms such as fatigue, muscle cramps, and comfort with the device. A follow-up visit will occur four weeks after the stimulation period ends. The goal of this pilot study is to determine whether home-based NMES is safe, feasible, and acceptable for individuals with ALS and to gather preliminary information about whether it may help slow muscle decline.

The goal of the DDRCC Biorepository is to collect human samples and health information to store for future research. Samples to be collected are blood, tissue (intestinal, liver, pancreas and/or lymph nodes), stool, and cheek swabs. Participants may be eligible to enroll if scheduled for a clinical visit or surgical procedure during which these samples could be collected.